236 related articles for article (PubMed ID: 25956422)
1. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
Pawloski PA; Larsen M; Thoresen A; Giordana MD
J Oncol Pharm Pract; 2016 Jun; 22(3):423-9. PubMed ID: 25956422
[TBL] [Abstract][Full Text] [Related]
2. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Kirshner JJ; McDonald MC; Kruter F; Guinigundo AS; Vanni L; Maxwell CL; Reiner M; Upchurch TE; Garcia J; Morrow PK
Support Care Cancer; 2018 Apr; 26(4):1323-1334. PubMed ID: 29147854
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim.
Moore DC; Gebru T; Pellegrino A; Fasan A; Patel J; Ringley JT
J Pharm Pract; 2020 Dec; 33(6):779-783. PubMed ID: 30917723
[TBL] [Abstract][Full Text] [Related]
8. Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report.
Romeo C; Li Q; Copeland L
J Oncol Pharm Pract; 2015 Aug; 21(4):301-4. PubMed ID: 24664474
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
11. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
12. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
[TBL] [Abstract][Full Text] [Related]
13. Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study.
Lower EE; Charif M; Bartelt M
Cancer Chemother Pharmacol; 2018 Jul; 82(1):165-170. PubMed ID: 29869680
[TBL] [Abstract][Full Text] [Related]
14. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.
Iwamoto H; Izumi K; Natsagdorj A; Makino T; Nohara T; Shigehara K; Kadono Y; Mizokami A
In Vivo; 2018; 32(4):899-903. PubMed ID: 29936477
[TBL] [Abstract][Full Text] [Related]
16. Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
Harbeck N; Wang J; Otto GP; Gattu S; Krendyukov A
Future Oncol; 2019 Apr; 15(12):1313-1322. PubMed ID: 30834780
[No Abstract] [Full Text] [Related]
17. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
[TBL] [Abstract][Full Text] [Related]
19. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Leung M; Florendo J; Kano J; Marr-Del Monte T; Higgins B; Myers R; Menon T; Jones G
Support Care Cancer; 2015 Jun; 23(6):1669-77. PubMed ID: 25421443
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.
Moukharskaya J; Abrams DM; Ashikaga T; Khan F; Schwartz J; Wilson K; Verschraegen C; Openshaw T; Valentine J; Eneman J; Unger P; Ades S
Support Care Cancer; 2016 Jul; 24(7):3085-93. PubMed ID: 26894485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
